Introduction
============

Congenital hypothyroidism (CH) is the most common endocrine diseases of childhood, leading to permanent mental retardation if not treated in the early infancy[@B1]. In industrialized countries, neonatal screening tests has enabled early diagnosis of CH in neonates, and consequently, severe mental retardation due to CH is very rare[@B2][@B3].

Due to the neonatal screening programs, the incidence of CH has increased in many countries around the world[@B4][@B5]. Further, improved thyroid stimulating hormone (TSH) assay sensitivity and lower cutoffs in the screening program have resulted in an increase in CH diagnoses. Owing to these changes in the newborn screening tests, the detection of mild forms of CH associated with eutopic and normal-shaped thyroid glands have increased progressively[@B6]. Current guidelines recommend that all children with CH need a re-evaluation of their thyroid function tests after 3 years of age; a condition where a levothyroxine treatment is no longer required to maintain normal thyroid function is classified as transient CH (TCH)[@B7].

In CH patients with eutopic thyroid gland, it is difficult to discriminate between TCH and permanent CH (PCH). There have been many studies on predictors that would allow an early detection of TCH, such as prematurity and the dose of levothyroxine during treatment[@B8][@B9][@B10]; however, no consensus has been achieved.

In the present study, we aimed to identify factors that could predict a transient form of CH in subjects with eutopic thyroid gland.

Materials and methods
=====================

1. Subjects
-----------

We retrospectively reviewed the medical records of all pediatric CH patients diagnosed between January 2003 and March 2015 at a single center of the University Hospital. In this period, total of 431 subjects were diagnosed with CH and received levothyroxine for at least 3 years. Of these 431 children with CH, 100 subjects showed a normal-shaped thyroid gland through a thyroid scan and/or thyroid ultrasound. CH was diagnosed on the basis of the following thyroid function test results: low serum free thyroxine (fT4), triiodothyronine (T3), and/or abnormal TSH (TSH\>10 IU/L) levels. The exclusion criteria were prematurity (gestational age\<37 weeks), low birth weight (\<2,500 g), birth asphyxia, congenital malformation, or chromosomal abnormalities and thyroid dysgenesis including agenesis, ectopic thyroid and small thyroid glands as identified by thyroid imaging studies. Subjects with central hypothyroidism of a hypothalamic or pituitary origin were also excluded.

2. Study design
---------------

All subjects with a confirmed CH diagnosis were immediately initiated on levothyroxine treatment and their TSH and thyroid hormone concentrations were tested every 3 months during the treatment period. The levothyroxine treatment was continued until 3 years of age and discontinued thereafter; thyroid function tests were re-evaluated 4 weeks posttherapy discontinuation. A normal thyroid function test at this time, indicating the maintenance of normal hormone concentrations without levothyroxine, confirmed the diagnosis of TCH, and levothyroxine was not administered thereafter. Non-maintenance of thyroid hormone concentrations without levothyroxine confirmed the diagnosis of PCH, and the diagnosed subjects received continuous hormone replacement therapy. At 3 years of age, subjects underwent thyroid imaging studies such as thyroid ultrasound and/or thyroid scan. All enrolled subjects were performed either thyroid ultrasounds and/or thyroid scan. Of 100 patients with CH, 83 and 95 subjects underwent thyroid ultrasound and thyroid scan, respectively. Data regarding gestational age, birth weight, levothyroxine dose, and age at treatment initiation were collected through a review of medical records.

3. Laboratory measurements
--------------------------

Serum fT4, T3, and TSH concentrations were measured using radioimmunoassays (RIAs) (Beckman Coulter, Fullerton, CA, USA). The analytical sensitivity of the utilized RIAs were ng/dL for fT4, 16.9 ng/dL for T3, and 0.04 µIU/mL for TSH. The normal reference ranges were 0.64--1.72 ng/dL for fT4, 76.2--190.1 ng/dL for T3, and 0.15--5.00 µIU/mL for TSH. The within-assay coefficients of variation (CVs) were 3.1%--10.29% for fT4, 3.7%--5.3% for T3, and 3.0%--3.7% for TSH, and the interassay CVs were 2.5%--7.5% for fT4, 4.4%--7.6% for T3, and 2.8%--8.6% for TSH.

4. Statistical analysis
-----------------------

Statistical analysis was performed using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA). For comparison of clinical parameters between the TCH and PCH groups, Student *t*-test was performed. To identify predictive factors associated with TCH, binary logistic regression test was performed for multivariate analysis with forward variable selection, with birth weight, gestational age, initial TSH and fT4 levels, and the levothyroxine dose as test variables. To evaluate the optimum cut-off levels of continuous biochemical predictors, we performed receiver operating characteristic (ROC) analyses with TCH as the dependent variable. Using the ROC analyses, we estimated the optimum values for all considered variables by calculating their Youden index (J), that is the maximum vertical distance between the ROC curve and the reference or chance line \[maximum (sensitivity + specificity -1)\][@B11]. Statistical significance was defined as *P*\<0.05. Results are described as mean±standard deviation unless otherwise stated.

Results
=======

Of the 100 subjects (53 boys and 47 girls), 35 (35.0%) were included in the PCH group and 65 (65.0%) were included in the TCH group based on the defined criteria. The ratio of sex was not significantly different between TCH and PCH groups (*P*=0.837). Subjects in the TCH group exhibited significantly lower TSH levels compared to subjects in the PCH group ([Table 1](#T1){ref-type="table"}). Further, the levothyroxine dose (per kg body weight) at the 1st, 2nd, and 3rd year of treatment were significantly lower in the TCH subjects ([Table 1](#T1){ref-type="table"}). However, subjects\' age at the time of treatment initiation, initial free T4 levels, and the initial levothyroxine dose were not significantly different between the 2 groups.

In a binary logistic regression analysis with birth weight, gestational age, initial TSH and fT4 levels, and the levothyroxine dose during the treatment period as independent variables, and TCH as the dependent variable, the initial TSH levels and the levothyroxine dose at the third year of treatment were significant predictors of a TCH diagnosis ([Table 2](#T2){ref-type="table"}).

According to the ROC curve analyses to estimate optimal cut-offs for individual TCH predictors, an optimal levothyroxine dose (at the third year of treatment) of 2.76 µg/kg/day was associated with a TCH diagnosis and demonstrated an 87.3% sensitivity and 67.6% specificity, with an area under the ROC curve of 0.769 ([Fig. 1](#F1){ref-type="fig"}). The initial TSH level value of 40.2 µIU/mL demonstrated a 61.9% sensitivity and 64.7% specificity, respectively (area under the ROC curve=0.636) ([Fig. 1](#F1){ref-type="fig"}).

Discussion
==========

In this study, subjects with normal-shaped thyroid gland in the TCH group exhibited significantly lower initial TSH levels and received lower levothyroxine dose during the treatment period than subjects in the PCH group. Furthermore, the levothyroxine dose at 3 years was significantly associated with TCH diagnosis, and a dose of 2.76 µg/kg at 3 years was the optimal cutoff value that could predict TCH.

In a previous study, Messina et al.[@B8] reported a TCH prevalence of 36.5% in 64 CH patients; however, subjects with ectopic thyroid gland were also included in the study. Ghasemi et al.[@B12] reported the prevalence of TCH was 3--4 times higher than permanent form with a prevalence rate of 1 in 294 live births. In a study in United States, of 33 children with primary diagnosed CH, 21 (64%) had PCH and 12 (36%) had TCH[@B13]. In Korean previous studies, the proportion of TCH among CH patients ranges from 39.4% to 54.9%[@B9][@B14][@B15]. In our study, 65.0% of the CH patients with eutopic thyroid gland were diagnosed with TCH. The higher proportion of TCH cases in our study could be due to the differences in sample size and inclusion criteria. Our study included only patients with normal shaped thyroid gland except thyroid dysgenesis like agenesis, hypoplasia, and ectopic thyroid gland. Therefore, our results indicate that about two-thirds of the CH patients with eutopic thyroid gland on the basis of neonatal screening tests may not require longer levothyroxine therapy as is the current guideline[@B8].

During the treatment period, the subjects in the TCH group demonstrated a lower requirement of levothyroxine than subjects in the PCH group. Moreover, the levothyroxine dose at the 3rd year of treatment was a positive predictor of TCH diagnosis. Skordis et al.[@B16] reported that patients with TCH who had a normal thyroid gland needed lower levothyroxine dose to maintain free T4 and TSH levels than patients with PCH. Unüvar et al.[@B17] reported that the levothyroxine dose required to maintain normal thyroid function was the only discriminatory marker between TCH and PCH cases. A study by Messina et al.[@B8] also reported a significant difference in the levothyroxine dose between the TCH and PCH groups. The study further reported that a levothyroxine dose of \<2.70, \<2.70, and \<2.05 at 1, 2, and 3 years of treatment, respectively, could predict a TCH diagnosis. Cho et al.[@B9] reported that subjects with TCH had significantly lower levothyroxine dose requirements at 1 and 2 years of treatment than PCH-affected subjects, and the cutoff value of the levothyroxine dose at 1 and 2 years was 3.25 µg/kg. In our study, a levothyroxine dose of 2.76 µg/kg at 3 years of treatment could distinguish between TCH and PCH.

Initial TSH levels could also predict TCH in CH-affected children with eutopic thyroid gland. In our study, the initial TSH levels at the time of CH diagnosis were significantly lower in subjects with TCH compared to those with PCH. Lim et al.[@B14] have similarly reported significantly lower initial TSH levels in the TCH patients. However, a few previous studies have reported that the initial fT4 and TSH levels could not differentiate between TCH and PCH cases[@B8][@B10][@B15].

The limitations of our study are a relatively small sample size and the retrospective study design. Also, we did not check factors that could affect thyroid function include iodine deficiency or excessive iodine intake, penetration of maternal thyroid auto-antibodies, and maternal drug history such as amiodarone. Finally, the sensitivity and specificity of cutoff value in ROC analysis were relatively low to predict TCH.

In conclusion, we demonstrated that the proportion of a transient form of CH were 65% of all CH patients with a normal shaped thyroid gland and TCH subjects had lower initial TSH levels and a lower levothyroxine dose requirement than PCH subjects. Therefore, TCH can be distinguished from PCH on the basis of the levothyroxine dose required to maintain normal thyroid function. Importantly, a levothyroxine dose lower than 2.76 µg/kg at 3 years may serve as a factor to predict TCH in CH patients with eutopic thyroid gland.
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###### Clinical and laboratory characteristics of the subjects (n=100)

![](apem-22-115-i001)

  Characteristic                      Total (n=100)   Transient CH (n=65)   Permanent CH (n=35)   *P*-value
  ----------------------------------- --------------- --------------------- --------------------- -----------
  Sex, male:female                    53:47           35:30                 18:17                 0.837^a)^
  Birth weight (kg)                   3.2±0.3         3.0±0.6               3.2±0.4               0.505
  Gestational age (wk)                39.3±1.1        38.1±2.9              39.2±1.7              0.265
  Age at treatment initiation (day)   26.7±13.3       27.3±14.3             25.6±11.3             0.550
  Free T4 (ng/dL)                     0.74±0.41       0.79±0.40             0.64±0.43             0.075
  T3 (ng/dL)                          131.8±40.2      135.5±37.7            124.4±44.4            0.204
  TSH (IU/L)                          37.9±26.0       30.8±18.8             47.1±33.8             0.005
  Levothyroxine dose (μg/kg)                                                                      
   Initial                            9.8±2.9         9.7±2.7               10.0±3.3              0.637
   1 yr                               3.6±1.0         3.4±0.8               4.1±1.3               0.009
   2 yr                               3.1±1.0         2.7±0.5               3.9±1.3               \<0.001
   3 yr                               2.6±0.9         2.3±0.5               3.3± 1.2              \<0.001

Values are presented as mean±standard deviation.

CH, congenital hypothyroidism; Free T4, free thyroxine; T3, triiodothyronine; TSH, thyroid stimulating hormone.

^a)^The ratio of sex was not significantly different between 2 groups using the chi-square test.

###### Binary logistic regression analysis of factors associated with transient congenital hypothyroidism (n=100, *r*^2^=0.313, *P* \<0.001)
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  Variable                                      Estimate   Standard error   *P*-value
  --------------------------------------------- ---------- ---------------- -----------
  TSH                                           0.028      0.012            0.021
  Levothyroxine dose at 3rd year of treatment   1.613      0.410            \<0.001

Regression analysis contained the following independent variables entered in to the model: birth weight; gestational age; initial TSH and free thyroxine levels; and the levothyroxine dose during treatment period.

TSH, thyroid stimulating hormone.
